TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24456059

Group type: EXPERIMENTAL
Intervention: Environmental enrichment (EE) for 2 hours daily starting 24 hours post-injury
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Simvastatin (Sim) for 2 hours daily starting 24 hours post-injury
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham group receiving saline for 14 days post-injury
Number of subjects: 7
Study: 22863900

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 179
Study: 20598958

Group type: EXPERIMENTAL
Intervention: Aquatic exercises
Number of subjects: 22

Group type: COMPARATOR
Intervention: Land-based exercises
Number of subjects: 22
Study: 18044283

Group type: EXPERIMENTAL
Intervention: Desflurane (group D, n=100)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n=100)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Propofol (group P, n=100)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study: 16042674

Group type: EXPERIMENTAL
Intervention: Candesartan (4 mg day(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Valsartan (40 mg day(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8
Study: 11240504

Group type: EXPERIMENTAL
Intervention: 6-hour expectancy group
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: 12-hour expectancy group
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: 24-hour expectancy group
Number of subjects: 713
Study: 9299823

Group type: EXPERIMENTAL
Intervention: Children under the age of two years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children from poorer households
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children with lack of running water, latrine, radio, or television in the household
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children with illiterate parents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breastfed children in the first two years of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children during the dry months of the year
Number of subjects: 0
Study: 8175622

Group type: EXPERIMENTAL
Intervention: T+K-Placebo (T group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: T+K (T+K group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: half-dose T+K (T/2 + K group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo of both T and K (P group)
Number of subjects: 55
Study: 2953870

Group type: EXPERIMENTAL
Intervention: Zoladex (sustained-release luteinizing hormone-releasing hormone analogue) administered by subcutaneous injection every 28 days
Number of subjects: 46
Study: 2383925

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 50 mU of biosynthetic human growth hormone (b‐hGH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous infusion of somatostatin (1‐14)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Infusions of exogenous hormone (3 mU/kg/h) for 15, 30, 60 and 180 min
Number of subjects: 10
Study: 796740

Group type: EXPERIMENTAL
Intervention: Intravenous iron 1-2 g every 4 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intravenous iron plus testosterone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intravenous iron and androgens
Number of subjects: 39
Study: 30457186

Group type: EXPERIMENTAL
Intervention: Phone call notification by a trained healthcare provider
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard letter notification
Number of subjects: 235
Study: 26735683

Group type: EXPERIMENTAL
Intervention: Alcohol condition: .10% peak breath alcohol concentration
Number of subjects: 70

Group type: COMPARATOR
Intervention: Attentional control instructions: none
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Attentional control instructions: 'relax and maximize' sexual arousal
Number of subjects: 70
Study: 25908281

Group type: EXPERIMENTAL
Intervention: Predictive model based on logistic regression derived from group 1 (n = 879)
Number of subjects: 1705

Group type: COMPARATOR
Intervention: Validation of predictive model in group 2 (n = 826)
Number of subjects: 1705
Study: 23641902

Group type: EXPERIMENTAL
Intervention: Campath (alemtuzumab)-based induction therapy
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Sirolimus-based maintenance therapy
Number of subjects: 852

Group type: COMPARATOR
Intervention: Basiliximab-based therapy
Number of subjects: 852

Group type: COMPARATOR
Intervention: Tacrolimus-based therapy
Number of subjects: 852
Study: 21555634

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Encoding-task fMRI
Number of subjects: 12
Study: 19345060

Group type: EXPERIMENTAL
Intervention: Multimodal intervention including standard treatment, supervised exercise program (4-6 weeks, 1 hour/day, 5 days/week), progressive relaxation, and psychoeducation.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment, care, and physiotherapy (control group).
Number of subjects: 42
Study: 16431880

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.8% vaporizer setting) with 4 litre min(‐1) N(2)O
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sevoflurane (1.8% or 3.6% vaporizer setting) in 6 litre min(‐1) O(2)
Number of subjects: 72
Study: 15534123

Group type: EXPERIMENTAL
Intervention: Tight BP control policy aiming for BP < 150/85 mm Hg
Number of subjects: 1148
Study: 11305517

Group type: EXPERIMENTAL
Intervention: New fecal calprotectin method with a cut-off limit of 50 microg/g
Number of subjects: 453

Group type: COMPARATOR
Intervention: Original fecal calprotectin method with a cut-off limit of 10 mg/l
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: New fecal calprotectin method with a cut-off limit of 150 microg/g
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Measurement of two spots in two stools
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin levels post-cancer removal
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Negative predictive value (NPV) for high risk population
Number of subjects: 453
Study: 9498146

Group type: EXPERIMENTAL
Intervention: Functional bracing (Group 1)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Locking nail (Group 2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 7634289

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2973777

Group type: EXPERIMENTAL
Intervention: Enoximone (low doses ≤ 1 mg/kg) in group A (n = 11)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Enoximone (high doses > 1 mg/kg) in group B (n = 12)
Number of subjects: 23
Study: 29111785

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus standard education
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 13
Study: 28849862

Group type: EXPERIMENTAL
Intervention: Dynamic orthosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 24610603

Group type: COMPARATOR
Intervention: 2% lidocaine gel (10 ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Liquid paraffin (10 ml)
Number of subjects: 40
Study: 23170749

Group type: EXPERIMENTAL
Intervention: Altitude training (ALT) at 2130 m for 19 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CON) at sea level for 19 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Altitude training (ALT)
Number of subjects: 30
Study: 21778294

Group type: EXPERIMENTAL
Intervention: Morphine (0.07 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 19786448

Group type: EXPERIMENTAL
Intervention: ED-based intervention including asthma symptom screening, a video addressing beliefs, and a mailed reminder.
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control group received instructions to follow-up with a PCP within 3 to 5 days.
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: ED-based intervention
Number of subjects: 433

Group type: COMPARATOR
Intervention: ED-based intervention and control group
Number of subjects: 433
Study: 17020434

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idraparinux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous methods for the exclusion of left atrial appendage
Number of subjects: 0
Study: 15236871

Group type: EXPERIMENTAL
Intervention: Electron boost (16Gy)
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: Photon boost (16Gy)
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: Interstitial boost (16Gy)
Number of subjects: 2661

Group type: COMPARATOR
Intervention: All boost techniques
Number of subjects: 2661
Study: 11553427

Group type: EXPERIMENTAL
Intervention: 5Rs procedure
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Adjunct questions (AQ)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Text only version of the booklet
Number of subjects: 51
Study: 9863075

Group type: EXPERIMENTAL
Intervention: TCM‐WM therapy (DMSA and Gandou decoction for 1 month)
Number of subjects: 80

Group type: COMPARATOR
Intervention: WM therapy (DMSA only)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (TCM‐WM and WM)
Number of subjects: 80
Study: 8142338

Group type: EXPERIMENTAL
Intervention: Low polyunsaturated:saturated fat (low P:S) diet
Number of subjects: 67

Group type: COMPARATOR
Intervention: High polyunsaturated:saturated fat (high P:S) diet
Number of subjects: 67
Study: 3283140

Group type: EXPERIMENTAL
Intervention: HUV grafts
Number of subjects: 90

Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 90
Study: 31599627

Group type: EXPERIMENTAL
Intervention: Duluth treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 31247165

Group type: COMPARATOR
Intervention: Active Exercise (AE) for 12 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Psychomotor Therapy (PMT) in combination with Active Exercise (AE) for 12 weeks
Number of subjects: 87
Study: 28279704

Group type: EXPERIMENTAL
Intervention: Pharmaceutical placebo
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Natural placebo
Number of subjects: 168
Study: 25897552

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 206

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 206
Study: 23149956

Group type: EXPERIMENTAL
Intervention: 20-degree PSO angle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40-degree PSO angle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 250 N/25 N testing with 20-degree PSO angle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40-degree PSO angle at 250 N/25 N
Number of subjects: 0
Study: 21270510

Group type: EXPERIMENTAL
Intervention: NCEP 2004 definition
Number of subjects: 3357

Group type: EXPERIMENTAL
Intervention: NCEP 2005 definition
Number of subjects: 3357

Group type: EXPERIMENTAL
Intervention: IDF definition
Number of subjects: 3357

Group type: EXPERIMENTAL
Intervention: Risk factors
Number of subjects: 3357
Study: 19371313

Group type: EXPERIMENTAL
Intervention: sildenafil 100 mg + sublingual GTN 400 microg
Number of subjects: 53

Group type: COMPARATOR
Intervention: placebo + sublingual GTN 400 microg
Number of subjects: 53
Study: 16791814

Group type: EXPERIMENTAL
Intervention: Radioiodine ablation of thyroid remnants with a standard activity of 3.7 GBq
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Radioiodine application of 300 MBq 131I after 3-6 months
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Radioiodine application of 7.4 GBq 131I after 5 days
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: External radiation therapy targeted on the neck and upper mediastinum
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Surgical treatment of newly formed lymph node metastases
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Overall treatment results
Number of subjects: 357
Study: 12736731

Group type: EXPERIMENTAL
Intervention: Satisfaction with Stroke Care questionnaire (SASC-19)
Number of subjects: 166
Study: 10695915

Group type: EXPERIMENTAL
Intervention: Cortisol infusion (6 microg kg(‐1) min(‐1)) during 6 h (group 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cortisol infusion (6 microg kg(‐1) min(‐1)) during 6 h (group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusion (group 3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusion (group 4)
Number of subjects: 24
Study: 9180060

Group type: EXPERIMENTAL
Intervention: Implantable defibrillators (ICDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional pharmaceutical therapy (primarily amiodarone)
Number of subjects: 0
Study: 1365014

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide mobilization (4 grams/m2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Post-reinfusion granulocyte/macrophage colony-stimulating factor
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PBSC collection after Cy mobilization
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neutrophil recovery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Time to platelet engraftment
Number of subjects: 24
Study: 4048477

Group type: EXPERIMENTAL
Intervention: Mechanical stretching of the uterus using a rubber catheter and balloon
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mechanical stretching of the uterus
Number of subjects: 6
Study: 31155673

Group type: EXPERIMENTAL
Intervention: Preoperative FFR measurement
Number of subjects: 67

Group type: COMPARATOR
Intervention: Visual estimation of coronary lesions
Number of subjects: 67
Study: 29514234

Group type: EXPERIMENTAL
Intervention: Enhanced prophylaxis (cotrimoxazole plus 12 weeks of isoniazid + fluconazole, single-dose albendazole, and 5 days of azithromycin)
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Enhanced prophylaxis
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Cotrimoxazole (control)
Number of subjects: 1805
Study: 25706553

Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cumulated Ambulation Score
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 30-s chair stand
Number of subjects: 52
Study: 23959817

Group type: EXPERIMENTAL
Intervention: Combination therapy (intratympanic methylprednisolone + oral steroid)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Oral steroid alone
Number of subjects: 79
Study: 21658194

Group type: EXPERIMENTAL
Intervention: Individually targeted information about the diagnosis and procedure by mail and phone
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard folder about colposcopies alone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Individually targeted information
Number of subjects: 149
Study: 19180895

Group type: EXPERIMENTAL
Intervention: Topical 0.1% methylene blue (MB) hydrogel with photodynamic therapy (PDT) using 565 mW LED 670 nm light
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topical 0.1% methylene blue (MB) hydrogel
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Histopathological examination post-treatment
Number of subjects: 16
Study: 17923598

Group type: EXPERIMENTAL
Intervention: Methylene blue (mean dose 1.3 ± 0.4 mg/kg)
Number of subjects: 28478

Group type: COMPARATOR
Intervention: Random sample of patients undergoing TEE (control group)
Number of subjects: 28478
Study: 15318852

Group type: EXPERIMENTAL
Intervention: 500 mg ASA 12 hours before apheresis (Group A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No medication before donation (Group B)
Number of subjects: 10
Study: 11262535

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg once daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9848591

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac supplemented by oral oxycodone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous morphine via patient‐controlled analgesia (PCA) device
Number of subjects: 90
Study: 9589816

Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg BID
Number of subjects: 952

Group type: COMPARATOR
Intervention: Cephalexin 500 mg QID
Number of subjects: 952
Study: 1884609

Group type: EXPERIMENTAL
Intervention: Polyclonal immunoglobulin preparation (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 55
Study: 6614408

Group type: EXPERIMENTAL
Intervention: New lancet with 1-mm point length
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Disposable hypodermic needle
Number of subjects: 142

Group type: COMPARATOR
Intervention: Lancet
Number of subjects: 142

Group type: COMPARATOR
Intervention: Needle
Number of subjects: 142

Group type: COMPARATOR
Intervention: Lancet and Needle
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Left arm reactions
Number of subjects: 142
Study: 31699029

Group type: EXPERIMENTAL
Intervention: Early continuous ultrafiltration (UF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous loop diuretics (LDs)
Number of subjects: 40
Study: 26709865

Group type: EXPERIMENTAL
Intervention: Imexon plus Gemcitabine
Number of subjects: 142

Group type: COMPARATOR
Intervention: Gemcitabine plus Placebo
Number of subjects: 142
Study: 26879671

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Enhanced Services as Usual (ESAU)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both conditions (MDFT and ESAU)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: MDFT
Number of subjects: 154
Study: 23895672

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (angioplasty or stenting)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 414

Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 414
Study: 22440436

Group type: EXPERIMENTAL
Intervention: Interactive computer‐based tool (CatInfo) containing a detailed audiovisual presentation about cataract and its treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham computer presentation without cataract‐related information
Number of subjects: 90
Study: 20080596

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18769351

Group type: EXPERIMENTAL
Intervention: darunavir/r 800/100 mg once daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: darunavir/r 600/100 mg twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: currently available PI(s) plus an optimized background regimen
Number of subjects: 80
Study: 15956111

Group type: EXPERIMENTAL
Intervention: Reduced salt intake
Number of subjects: 112
Study: 12388173

Group type: COMPARATOR
Intervention: Nandrolone decanoate weekly (group 1)
Number of subjects: 30
Study: 9659025

Group type: EXPERIMENTAL
Intervention: mivacurium 0.04 mg.kg‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: mivacurium 0.08 mg.kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: propofol 2.5 mg.kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 90
Study: 8070508

Group type: EXPERIMENTAL
Intervention: Oral Cyclosporin (CsA) solution (mean daily dose: 23.3 mg.kg‐1) in CF subjects
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral Cyclosporin (CsA) solution in non-CF subjects (mean daily dose: 4.8 mg.kg‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pancreatic enzymes (Creon) and ranitidine in CF subjects
Number of subjects: 10
Study: 2904313

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (0.25 to 8 micrograms min‐1 kg‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoclopramide infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dopamine infusion
Number of subjects: 20
Study: 30453906

Group type: EXPERIMENTAL
Intervention: Families Fighting Cancer Together (FFCT) intervention
Number of subjects: 172

Group type: COMPARATOR
Intervention: Parent-only psycho-educational (PED) program
Number of subjects: 172
Study: 27923968

Group type: EXPERIMENTAL
Intervention: Self-Directed weight loss maintenance intervention
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Guided phone-based weight loss maintenance intervention
Number of subjects: 419
Study: 25826767

Group type: EXPERIMENTAL
Intervention: Commercial programme (CP; Weight Watchers)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Both groups (CP and SC)
Number of subjects: 772
Study: 23788305

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 14
Study: 20517305

Group type: EXPERIMENTAL
Intervention: VSL#3 (3,600 billion CFU/day)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 17936283

Group type: EXPERIMENTAL
Intervention: Hyaluronan-enriched transfer medium (HETM)
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Conventional embryo transfer medium
Number of subjects: 1282
Study: 16093516

Group type: EXPERIMENTAL
Intervention: Internet-based treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard medical care waitlist (Control)
Number of subjects: 47
Study: 14508327

Group type: EXPERIMENTAL
Intervention: Acetazolamide (5 mg/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 38
Study: 10662918

Group type: EXPERIMENTAL
Intervention: Ulnar forearm flap
Number of subjects: 67

Group type: COMPARATOR
Intervention: Radial forearm flap
Number of subjects: 67
Study: 9037361

Group type: EXPERIMENTAL
Intervention: Filgrastim 1.0 microgram/kg s.c. daily for 3‐7 days followed by CEOP with filgrastim support 10 micrograms/kg s.c. daily, day 2‐14
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CEOP chemotherapy (C 500 mg/m2, E 37.5 mg/m2, O 2 mg, P 75 mg/m2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CEOP chemotherapy (C 750 mg/m2, E 50 mg/m2, O 2 mg, P 75 mg/m2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Filgrastim support
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 14
Study: 1577056

Group type: EXPERIMENTAL
Intervention: Theophylline 5 mg.kg-1 per day with omeprazole 20 mg per day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Theophylline 5 mg.kg-1 per day with placebo
Number of subjects: 8